{"id":7822,"date":"2014-04-04T16:35:29","date_gmt":"2014-04-04T16:35:29","guid":{"rendered":""},"modified":"2014-04-04T16:35:29","modified_gmt":"2014-04-04T16:35:29","slug":"sirdies-ir-kraujagysliu-ligu-prevencijos-acetilsalicilo-rugstimi-galimybes","status":"publish","type":"post","link":"https:\/\/www.pasveik.lt\/lt\/naujausi-medicinos-straipsniai\/sirdies-ir-kraujagysliu-ligu-prevencijos-acetilsalicilo-rugstimi-galimybes\/7822\/","title":{"rendered":"\u0160irdies ir kraujagysli\u0173 lig\u0173 prevencijos acetilsalicilo r\u016bg\u0161timi galimyb\u0117s"},"content":{"rendered":"<p class=\"Pa15\" style=\"text-align: justify;\"><strong>\u012evadas <\/strong><\/p>\n<p class=\"Pa7\" style=\"text-align: justify;\">Daugeliu tyrim\u0173 \u012frodyta, kad ilgalaikis acetilsa\u00adlicilo r\u016bg\u0161ties vartojimas veiksmingai, apie 25 proc., suma\u017eina \u0161irdies ir kraujagysli\u0173 sistemos nepalan\u00adki\u0173 \u012fvyki\u0173 (nemirtino miokardo infarkto (MI), ne\u00admirtino insulto ir mir\u0161tamumo d\u0117l kardiovaskulini\u0173 prie\u017eas\u010di\u0173) rizik\u0105 ir yra tinkamas antrinei MI ir in\u00adsulto profilaktikai. Absoliu\u010diais skai\u010diais tai atitinka suma\u017e\u0117jim\u0105 apie 10\u201320 nepalanki\u0173 \u012fvyki\u0173 1 t\u016bkst. pacient\u0173 per metus. Kiek ma\u017eiau vartojant acetilsa\u00adlicilo r\u016bg\u0161t\u012f suma\u017e\u0117ja ir mir\u0161tamumas d\u0117l kardiovas\u00adkulini\u0173 prie\u017eas\u010di\u0173. Acetilsalicilo r\u016bg\u0161ties veiksmin\u00adgumas ir saugumas i\u0161tirtas daugeliu tyrim\u0173. Seniai \u017einoma ir apie kraujavimus, kurie da\u017enesni vartojant acetilsalicilo r\u016bg\u0161t\u012f, ta\u010diau \u012frodyta, kad kardiovas\u00adkulini\u0173 \u012fvyki\u0173 prevencijai vartojam\u0173 ma\u017e\u0173 acetilsa\u00adlicilo r\u016bg\u0161ties dozi\u0173 nauda vir\u0161ija kraujavimo rizi\u00adk\u0105. \u017dinoma ir apie acetilsalicilo r\u016bg\u0161ties dirginam\u0105\u00adj\u012f poveik\u012f skrand\u017eio gleivinei, tod\u0117l sukurtos nau\u00adjos kartos pl\u0117vele dengtos tablet\u0117s, kurios apsaugo skrand\u017eio gleivin\u0119 ir pagerina gydymo toleravim\u0105. Vis d\u0117lto tyrimo EUROASPIRE rezultatai rodo, kad Lietuvoje gydytojai per ma\u017eai skiria, o paci\u00adentai per ma\u017eai varto\u00adja acetilsalicilo r\u016bg\u0161\u00adt\u012f ir kitus trombocit\u0173 funkcijas slopinan\u010dius vaistus.<\/p>\n<p class=\"Pa15\" style=\"text-align: justify;\"><strong>Tyrimas EUROASPIRE <\/strong><\/p>\n<p class=\"Pa7\" style=\"text-align: justify;\">Tyrimas EUROAS\u00adPIRE atliktas siekiant \u012fvertinti, kaip Europoje \u0161eimos gydytojai, kar\u00addiologai ir kiti specia\u00adlistai laikosi i\u0161emin\u0117s \u0161irdies ligos (I\u0160L) pre\u00advencijos rekomendaci\u00adj\u0173 pacientams, kuriems diagnozuoti daugybi\u00adniai I\u0160L rizikos veiks\u00adniai, bei pacientams, kurie jau serga I\u0160L, antrinei kardiovaskulini\u0173 \u012fvyki\u0173 prevencijai. Taip pat ty\u00adrime \u012fvertinti da\u017eniausi I\u0160L rizikos veiksniai ir j\u0173 paplitimas. Tyrimas EUROASPIRE IV atliktas 24 Europos \u0161alyse, juo siekta \u012fvertinti gyvenimo \u012fpro\u00ad\u010di\u0173 poky\u010dius, da\u017eniausius rizikos veiksnius susir\u00adgus I\u0160L, \u012fvertinti kardioprotekcini\u0173 medikament\u0173 vartojim\u0105. Nustatyta, kad Lietuva labiausiai i\u0161 ty\u00adrime dalyvavusi\u0173 \u0161ali\u0173 atsilieka pagal acetilsalici\u00adlo r\u016bg\u0161ties ir kit\u0173 trombocit\u0173 funkcijas slopinan\u010di\u0173 vaist\u0173 vartojim\u0105 (<em>1 pav.<\/em>).<\/p>\n<p class=\"Pa7\"><img decoding=\"async\" src=\"data:image\/jpeg;base64,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\n<\/p>\n","protected":false},"excerpt":{"rendered":"<p style=\"text-align: justify;\">Daugeliu tyrim\u0173 \u012frodyta, kad ilgalaikis acetilsa\u00adlicilo r\u016bg\u0161ties vartojimas veiksmingai, apie 25 proc., suma\u017eina \u0161irdies ir kraujagysli\u0173 sistemos nepalan\u00adki\u0173 \u012fvyki\u0173 (nemirtino miokardo infarkto (MI), ne\u00admirtino insulto ir mir\u0161tamumo d\u0117l kardiovaskulini\u0173 prie\u017eas\u010di\u0173) rizik\u0105 ir yra tinkamas antrinei MI ir in\u00adsulto profilaktikai. Absoliu\u010diais skai\u010diais tai atitinka suma\u017e\u0117jim\u0105 apie 10\u201320 nepalanki\u0173 \u012fvyki\u0173 1 t\u016bkst. pacient\u0173 per metus. Kiek ma\u017eiau vartojant acetilsa\u00adlicilo r\u016bg\u0161t\u012f suma\u017e\u0117ja ir mir\u0161tamumas d\u0117l kardiovas\u00adkulini\u0173 prie\u017eas\u010di\u0173.<\/p>\n","protected":false},"author":1,"featured_media":7823,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[27313],"tags":[3746,3745,1143,50,205,141,24,3744,3670,177,64,3747,923,55,181],"site":[],"post_item_type":[27345],"class_list":["post-7822","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-gydymo-naujienos","tag-acetilsalicilo-rugsties-poveikis","tag-acetilsalicilo-rugstis","tag-angina","tag-dispepsija","tag-gydytojai","tag-insultas","tag-profilaktikai","tag-rugsti","tag-rugstis","tag-skausmui","tag-tabletes","tag-tabletes-dengtos-plevele","tag-veiklioji","tag-virskinimo","tag-visiems"],"acf":{"post_sites":false},"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.pasveik.lt\/lt\/wp-json\/wp\/v2\/posts\/7822","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.pasveik.lt\/lt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pasveik.lt\/lt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pasveik.lt\/lt\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pasveik.lt\/lt\/wp-json\/wp\/v2\/comments?post=7822"}],"version-history":[{"count":0,"href":"https:\/\/www.pasveik.lt\/lt\/wp-json\/wp\/v2\/posts\/7822\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.pasveik.lt\/lt\/wp-json\/wp\/v2\/media\/7823"}],"wp:attachment":[{"href":"https:\/\/www.pasveik.lt\/lt\/wp-json\/wp\/v2\/media?parent=7822"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pasveik.lt\/lt\/wp-json\/wp\/v2\/categories?post=7822"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pasveik.lt\/lt\/wp-json\/wp\/v2\/tags?post=7822"},{"taxonomy":"site","embeddable":true,"href":"https:\/\/www.pasveik.lt\/lt\/wp-json\/wp\/v2\/site?post=7822"},{"taxonomy":"post_item_type","embeddable":true,"href":"https:\/\/www.pasveik.lt\/lt\/wp-json\/wp\/v2\/post_item_type?post=7822"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}